EZH2, an epigenetic driver of prostate cancer
Protein & Cell
;
(12): 331-341, 2013.
Artigo
em Inglês
| WPRIM
| ID: wpr-757802
ABSTRACT
The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Patologia
/
Neoplasias da Próstata
/
Regulação Neoplásica da Expressão Gênica
/
Metilação de DNA
/
Epigênese Genética
/
Tratamento Farmacológico
/
Terapia de Alvo Molecular
/
Complexo Repressor Polycomb 2
/
Proteína Potenciadora do Homólogo 2 de Zeste
/
Genética
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Protein & Cell
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS